This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n12http://localhost/temp/predkladatel/
n18http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n10http://linked.opendata.cz/resource/domain/vavai/projekt/
n8http://linked.opendata.cz/resource/domain/vavai/subjekt/
n7http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n14http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61989592%3A15310%2F11%3A33118107%21RIV12-GA0-15310___/
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n9http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61989592%3A15310%2F11%3A33118107%21RIV12-GA0-15310___
rdf:type
n7:Vysledek skos:Concept
dcterms:description
Proteasome inhibition is a modern and surprisingly successful approach how to cancer treatment. Bortezomib(Velcade (R)) is a first-in-class proteasome inhibitor and has been approved for first-line treatment of multiple myeloma and second-line treatment of mantle cell lymphoma. There have been almost 200 clinical trials with bortezomib, both as a single agent and in combination with other drugs, for various cancers, as listed in the US National Cancer Institute database. However, bortezomib's mechanism of action remains elusive despite enormous progress in our knowledge of the cell biology of the ubiquitin-proteasome system (UPS) and bortezomib-induced signaling events in cancer cells. This review maps a rapidly growing and open body of research in both areas. Proteasome inhibition is a modern and surprisingly successful approach how to cancer treatment. Bortezomib(Velcade (R)) is a first-in-class proteasome inhibitor and has been approved for first-line treatment of multiple myeloma and second-line treatment of mantle cell lymphoma. There have been almost 200 clinical trials with bortezomib, both as a single agent and in combination with other drugs, for various cancers, as listed in the US National Cancer Institute database. However, bortezomib's mechanism of action remains elusive despite enormous progress in our knowledge of the cell biology of the ubiquitin-proteasome system (UPS) and bortezomib-induced signaling events in cancer cells. This review maps a rapidly growing and open body of research in both areas.
dcterms:title
The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
skos:prefLabel
The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
skos:notation
RIV/61989592:15310/11:33118107!RIV12-GA0-15310___
n7:predkladatel
n8:orjk%3A15310
n3:aktivita
n15:P
n3:aktivity
P(GAP304/10/0149), P(GP303/08/P137)
n3:cisloPeriodika
15
n3:dodaniDat
n9:2012
n3:domaciTvurceVysledku
n18:9131795 n18:8069239
n3:druhVysledku
n16:J
n3:duvernostUdaju
n19:S
n3:entitaPredkladatele
n14:predkladatel
n3:idSjednocenehoVysledku
236440
n3:idVysledku
RIV/61989592:15310/11:33118107
n3:jazykVysledku
n11:eng
n3:klicovaSlova
mechanism of action; bortezomib; Ubiquitin-proteasome system
n3:klicoveSlovo
n4:mechanism%20of%20action n4:Ubiquitin-proteasome%20system n4:bortezomib
n3:kodStatuVydavatele
AE - Stát Spojené arabské emiráty
n3:kontrolniKodProRIV
[81925EB9C101]
n3:nazevZdroje
Current Pharmaceutical Design
n3:obor
n17:FR
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
2
n3:projekt
n10:GP303%2F08%2FP137 n10:GAP304%2F10%2F0149
n3:rokUplatneniVysledku
n9:2011
n3:svazekPeriodika
17
n3:tvurceVysledku
Cvek, Boris Dvořák, Zdeněk
n3:wos
000295455800010
s:issn
1381-6128
s:numberOfPages
17
n12:organizacniJednotka
15310